Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Koichi Ashizaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nomura Dermatology Clinic, Yokohama, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Erythema, Machine Learning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Agency for Medical Research and Development (AMED), Grant for Encouragement of Clinical Research on Atopic Dermatitis, Presentation Award at the 121st Annual Meeting of the Japanese Dermatological Association.
Abstract (Originalsprache)
Background
Persistent facial erythema represents a significant complication in atopic dermatitis (AD) patients undergoing treatment with dupilumab. Stratifying patients based on the erythema course is crucial for elucidating heterogeneous phenotypes and facilitating advanced drug efficacy predictions.
Objectives
This study aimed to identify factors associated with facial erythema severity in dupilumab‐treated AD patients and to establish a prediction model for drug response based on the identified factors.
Methods
Data from a retrospective study conducted between July 2018 and July 2021 were collected and analysed. Patients were categorized into three groups via hierarchical clustering based on the course of facial erythema: early remission, low remission and persistent residual. LightGBM, a supervised gradient boosting decision tree algorithm, was employed to discern group differences and construct a prediction model. The model incorporated patient demographic and clinical profiles, including pre‐ and post‐treatment examinations. The model's performance was evaluated using accuracy and the area under the receiver operating characteristic curve (AUC).
Results
The binary classification model demonstrated an accuracy of 89.10% and an AUC of 0.862 when distinguishing between early remission and persistent residual patients. The eight prominent factors associated with facial erythema severity included age, sex, lactate dehydrogenase (LDH), immunoglobulin E (IgE), eosinophil count, white blood cell count, Alnus allergy and cedar allergy.
Conclusions
This study has two main significances: first, three clusters were identified through unsupervised learning; second, a classification model was constructed that proved more accurate than random prediction. The stratification and identification of crucial factors associated with residual facial erythema in dupilumab‐treated AD patients lay the foundation for AI‐powered prognostic models. This groundwork provides a substantial basis for enhancing future medical AI support in AD treatment selection, potentially improving personalized treatment approaches and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nomura Dermatology Clinic, Yokohama, Japan.
- Advanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, RIKEN, Yokohama, Japan.
- Collective Intelligence Research Laboratory, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
- Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Koichi Ashizaki, Tetsuo Ishikawa, Yuko Nomura
Förderung
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Japan Agency for Medical Research and Development (AMED)
- Grant for Encouragement of Clinical Research on Atopic Dermatitis, Presentation Award at the 121st Annual Meeting of the Japanese Dermatological Association
- Japan Society for the Promotion of Science
Zitieren
APA
Ashizaki, K., Ishikawa, T., & Nomura, Y. (2024). Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19909
Vancouver
Ashizaki K, Ishikawa T, Nomura Y. Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19909
BibTeX
@article{Ashizaki2024,
author = {Ashizaki, Koichi and Ishikawa, Tetsuo and Nomura, Yuko},
title = {Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19909}
}
EUVIMED